Neurosciences

Movement disorders

Pablo Mir Rivera
IBiS
Campus Hospital Universitario Virgen del Rocío
Avda. Manuel Siurot, s/n.
41013 · Sevilla

Laboratory: 104
Foto no disponible
IBiS
Campus Hospital Universitario Virgen del Rocío
Avda. Manuel Siurot, s/n.
41013 · Sevilla
Laboratory: 104

Pablo Mir Rivera

Back to program
  1. Group members
  2. Research areas
  3. Publications
  4. News

Group: Movement disorders

Directory
Group members Movement disorders
  • Álvarez de Toledo Blandón, Mª Paloma.Lda. Psicología.
  • Bernal Bernal, Inmaculada.Degree in Biology. Technician.
  • Bernal Escudero, Maravilla.Diplomada en Enfermería
  • Bonilla Toribio, Marta.Degree in Biology. Technician.
  • Carballo Cordero, Manuel.MD/PhD. Faculty Staff - Neurology (HUVR).
  • Carrillo García, Fátima.Degree in Medicine. Faculty Staff - Neurology (HUVR).
  • Gómez Garre, María del Pilar.PhD in Biology. Post-doctoral fellow (Miguel Servet).
  • Gómez-Feria Ferreiro, José.Becario FPU
  • Huertas Fernández, Ismael.Telecommunications Engineer. Technician
  • Jesús Maestre, Silvia.Degree in Medicine. Faculty Staff - Neurology (HUVR).
  • Lama Suárez, María José.Degree in Psychology. PhD student.
  • Lopes Ramos, Teresa da Conceiçao.Dra. en Biociencias
  • Macías García, Daniel.MIR HUVR
  • Madruga Garrido, Marcos.Degree in Medicine. Faculty Staff - Neurology (HUVR).
  • Martín Rodríguez , Juan Francisco .Doctor en Neurociencias
  • Méndez del Barrio, Carlota.Lda. en Medicina. Técnico de Apoyo.
  • Mir Rivera, Pablo.MD/PhD. Faculty Staff/Assistant Professor. (HUVR/University of Seville).
  • Oropesa Ruíz, Juan Manuel.Ldo. en Medicina.
  • Palomar Simón, Francisco.Degree in Medicine. Post-MIR.
  • Periñán Tocino, Mª Teresa.Investigadora en Formación FPU
  • Porcacchia, Paolo.Degree in Medicine. Faculty Staff - Neurology (HUVR).
  • Ribas Serna, Juan.Catedrático US
  • Rodríguez Baena, Antonio.Ldo. en Informática. Técnico.
  • Romero Castillo, Rocío.Técnico de Apoyo
  • Rubio Agustí, Ignacio.Ldo. en Medicina.
  • Tejera Parrado, Cristina .Lda. en Biotecnología. Predoctoral.
  • Vargas González, Laura.Diploma of Nursing.

Research areas

Our group focuses its research on two main areas:

Study of genetic factors involved in the pathogenesis of Parkinson's disease (PD) and other movement disorders.

In the last few years numerous genes related to the pathophysiology of movement disorders have been described. Our group is interested in the characterisation of these genes, as well as of other possible candidate genes. Our final objective is to investigate the functional consequences of the alterations of these genes in our population by means of the phenotype-genotype correlation analysis and studies of genetic linkage

Transcraneal magnetic stimulation (TMS) in the study of the pathophysiology of PD and other movement disorders.

In this line our group attempts to evaluate, using TMS, the role of various areas of the brain in the pathophysiology of PD and other movement disorders, as well as their modulation by drugs, functional surgery and genetic factors.

Studies of the clinical aspects of PD and other movement disorders.

The objective of this line is focussed on the more clinical aspects of movement disorders, describing unusual presentations of different diseases and differential clinical characteristics of some entities. The study of the efficacy of various therapies is also included, as well as the diagnostic value of different neuroimaging tests in PD and other movement disorders.

International Journals
Jesús S, Pérez I, Cáceres-Redondo MT, Carrillo F, Carballo M, Gómez-Garre P, Mir P
Low serum uric acid concentration in Parkinson’s disease in southern Spain.
European Journal of Neurology 2013;20(1):208-210
Benítez-Rivero S, Marín-Oyaga VA, García-Solís D, Huertas-Fernández I, García-Gómez FJ, Jesús S, Cáceres MT, Carrillo F, Ortiz AM, Carballo M, Mir P
Clinical features and 123I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson's disease
J Neurol Neurosurg Psychiatry 2013;84(2):122-129.
Mata IF, Alvarez V, Ribacoba R, Infante J, Sierra M, Gómez-Garre P, Mir P, Waldherr S, Yearout D, Zabetian CP
Novel Lrrk2-p.S1761R mutation is not a common cause of Parkinson's disease in Spain.
Movement Disorders 2013;28(2):248
Palomar FJ, Suárez A, Franco E, Carrillo F, Gil-Néciga E, Mir
Abnormal sensorimotor plasticity in CADASIL correlates with neuropsychological impairment.
J Neurol Neurosurg Psychiatry 2013;84(3):329-336
Conde V, Palomar FJ, Lama MJ, Martínez R, Carrillo F, Pintado E, Mir P
Abnormal GABA-mediated and cerebellar inhibition in women with the fragile X premutation.
Journal of Neurophysiology 2013;109(5):1315-1322
Palomar FJ, Conde V, Carrillo F, Fernández-del-Olmo M, Koch G, Mir P
Parieto-motor functional connectivity is impaired in Parkinson’s disease.
Brain Stimulation 2013;6(2):147-154.
Carrillo F, Palomar FJ, Conde V, Diaz-Corrales FJ, Porcacchia P, Fernández-Del-Olmo M, Koch G, Mir P
Study of cerebello-thalamocortical pathway by transcranial magnetic stimulation in Parkinson's disease.
Brain Stimulation 2013;6(4):582-589.
González-Aramburo I, Sanchez-Juan P, Jesús S, Gorostidi A, Fernández-Juan E, Carrillo F, Sierra F, Gómez-Garre P, Cáceres-Redondo MT, Berciano J, Ruí-Martínez J, Combarros O, Mir P, Infante J
Genetic variability related to serum uric acid concentration and risk of Parkinson’s disease.
Movement Disorders 2013 (en prensa)
Kojovic M, Pareés I, Kassavetis P, Palomar F, Mir P, Teo J, Cordivari C, Rothwell JC, Bhatia KP, Edwards MJ
Secondary and primary dystonia –pathophysiological differences.
Brain 2013;136(7):2038-2049.
Jesús S, Gómez-Garre P, Carrillo F, Cáceres-Redondo MT, Huertas-Fernández I, Bernal-Bernal I, Bonilla-Toribio M, Vargas-González L, Carballo M, Mir P
Genetic association of sirtuin genes and Parkinson’s disease
Journal of Neurology 2013 (en prensa).
Jesús S, Cáceres-Redondo MT, Carrillo F, Cordones I, Escudero M, Macías-Vidal J, Coll MJ, Bautista J, Mir P
Adult form of Niemann-Pick type C with the variant biochemical phenotype on treatment with Miglustat.
Parkinsonism and Related Disorders 2013 (en prensa)
García-Gómez FJ, García-Solís D, Luis-Simón FJ, Marín-Oyaga VA, Carrillo F, Mir P, Vázquez-Albertino RJ.
[Elaboration of the SPM template for the standardization of SPECT images with <sup>123</sup>I-Ioflupane.]
Revista Española de Medicina Nuclear e Imagen Molecular 2013 (en prensa).
García-Ramos R, López Valdés E, Ballesteros L, Jesús S, Mir P
Informe de la Fundación del Cerebro sobre el impacto social de la enfermedad de Parkinson en Espana.
Neurología 2013 (en prensa).
Karagiannidis I, Dehning S, Sandor P, Tarnok Z, Rizzo R, Wolanczyk T, Madruga-Garrido M, Hebebrand J, Nöthen MM, Lehmkuhl G, Farkas L, Nagy P, Szymanska U, Anastasiou Z, Stathias V, Androutsos C, Tsironi V, Koumoula A, Barta C, Zill P, Mir P, Müller N, Barr C, Paschou P.
Support of the histaminergic hypothesis in Tourette Syndrome: association of the histamine decarboxylase gene in a large sample of families.
J Med Genet. 2013
Mata IF, Alvarez V, Ribacoba R, Infante J, Sierra M, Gómez-Garre P, Mir P, Waldherr S, Yearout D, Zabetian CP.
Novel Lrrk2-p.S1761R mutation is not a common cause of Parkinson's disease in Spain.
Rev Esp Med Nucl Imagen Mol. 2013

News

RETOS-COLABORACIÓN 2015 - MIR RIVERA, PABLO RTC-2015-3309-1 financiado por MINISTERIO DE ECONOMÍA Y COMPETITIVIDAD

gobierno-espana-ministerio-economia-y-competitividad-ue

Título: “Desarrollo de una terapia para el tratamiento de variantes genéticas de α-sinucleína en la enfermedad de Parkinson”

El objetivo de este proyecto es el desarrollo de una terapia basada en el compuesto NLF-PD-1233 (de nLife), dirigido a los pacientes con enfermedad de Parkinson que presentan alteraciones en la expresión del gen de la alfa-sinucleína.

La selección de pacientes en función de sus variantes génicas permitirá normalizar la población en estudio y obtener una mayor fortaleza en los estudios de identificación de nuevos biomarcadores.

Para la búsqueda de biomarcadores se evaluará la eficacia del tratamiento con NLF-PD-1233 en un modelo in-vitro de progresión de la enfermedad en células IPCs de pacientes que presentan estas alteraciones del gen SNCA. Por otra parte, el consorcio estudiará biomarcadores subrogados al tratamiento con NLF-PD-1233 asociados a neuroinflamación, neurodegeneración, medidas de viabilidad celular, función neuronal, microPET y estudios de comportamiento, en modelos in-vitro, in-vivo y en un modelo de administración crónica de MPTP en ratones transgénicos que presentan duplicación o triplicación del gen SNCA y las mutaciones puntuales del SNCA más abundantes.